nye-MOE-di-peen
Therapeutic Classification: subarachnoid hemorrhage therapy agents
Pharmacologic Classification: calcium channel blockers
Absorption: Well absorbed following oral administration but undergoes first-pass metabolism, resulting in ↓ bioavailability.
Distribution: Crosses the blood-brain barrier; remainder of distribution unknown.
Protein Binding: >95%.
Half-Life: 1–2 hr.
Contraindicated in:
Use Cautiously in:
CV: ARRHYTHMIAS, chest pain, HF, hypotension, palpitations, peripheral edema, syncope, tachycardia
Derm: ↑sweating, dermatitis, ERYTHEMA MULTIFORME, flushing, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME (SJS)
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus
Endo: gynecomastia, hyperglycemia
GI: ↑liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency
Hemat: anemia, leukopenia, thrombocytopenia
MS: joint stiffness, muscle cramps
Neuro: abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, headache, nervousness, paresthesia, psychiatric disturbances, tremor, weakness
Misc: gingival hyperplasia
Drug-drug:
Drug-Natural Products:
Hepatic Impairment
Lab Test Considerations:
NDC Code